Seer Inc - Ordinary Shares - Class A Stock

$2.12

2.91% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US81578P1066

Symbol

SEER

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Seer Inc - Ordinary Shares - Class A Stock price

$2.12

-16.88 88.84% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.06 2.91%

ISIN

US81578P1066

Symbol

SEER

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$124.8m

Enterprise Value

$-115.0m

Net debt

$-239.7m

Cash

$239.7m

Shares outstanding

59.4m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

8.15 | 6.98

EV/Sales

negative | negative

EV/FCF

2.27

P/B

0.41

Financial Health

Equity Ratio

89.35%

Return on Equity

-26.44%

ROCE

-28.63%

ROIC

-93.41%

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$15.3m | $17.9m

EBITDA

$-89.4m | $-86.8m

EBIT

$-95.6m

Net Income

$-85.9m | $-86.4m

Free Cash Flow

$-50.6m

Growth (TTM | estimate)

Revenue

-2.30% | 26.18%

EBITDA

6.32% | 7.58%

EBIT

5.51%

Net Income

-3.46% | 0.25%

Free Cash Flow

13.04%

Margin (TTM | estimate)

Gross

50.66%

EBITDA

-583.71% | -485.50%

EBIT

-624.73%

Net

-560.90% | -483.12%

Free Cash Flow

-330.22%

EPS

$-1.44

FCF per Share

$-0.85

Short interest

3.35%

Employees

147.00

Rev per Employee

$100.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Seer Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Seer Inc - Ordinary Shares - Class A forecast:

6x Buy

67%

3x Hold

33%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Seer Inc - Ordinary Shares - Class A forecast:

Buy

67%

Hold

33%

Analyst Estimates with Stock Price Targets

Financial data from Seer Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	15 15	2% 2% 100%
- Direct Costs	7.55 7.55	4% 4% 49%
Gross Profit	7.76 7.76	1% 1% 51%
- Selling and Administrative Expenses	54 54	8% 8% 351%
- Research and Development Expense	50 50	2% 2% 324%
EBITDA	-89 -89	6% 6% -584%
- Depreciation and Amortization	6.28 6.28	8% 8% 41%
EBIT (Operating Income) EBIT	-96 -96	6% 6% -625%
Net Profit	-86 -86	3% 3% -561%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Seer Inc - Ordinary Shares - Class A Stock News

Neutral

GlobeNewsWire

●

27 days ago

Seer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults

First-of-its-kind study will use Seer's next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics

Neutral

GlobeNewsWire

●

30 days ago

Seer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and Efficiency

REDWOOD CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the launch of its new Proteograph® Product Suite, featuring the Proteograph ONE Assay and SP200 Automation Instrument—its most advanced solution yet for scalable, high-resolution, mass spec-based proteomics.

Neutral

Seeking Alpha

●

about 2 months ago

Seer, Inc. (SEER) Q1 2025 Earnings Call Transcript

Seer, Inc. (NASDAQ:SEER ) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Kelly Gura - Investor Relations Omid Farokhzad - Chief Executive Officer and Chair of the Board David Horn - Chief Financial Officer and President Conference Call Participants Rachel Vatnsdal - JPMorgan Operator Good day, and thank you for standing by. Welcome to Seer first quarter 2025 earnin...

More Seer Inc - Ordinary Shares - Class A News

Company Profile

Seer, Inc. (California) engages in the development of proprietary engineered nanoparticles to provide access across the proteome. Its Proteograph product suite comprises automation instrument and software, which provides workflow to make proteomic profiling. The company was founded by Philip Ma, Robert S. Langer Jr., and Omid C. Farokhzad on March 16, 2017 and is headquartered in Redwood City, CA.

Head office	United States
CEO	Omid Farokhzad
Employees	147
Founded	2017
Website	seer.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now